356 filings
Page 15 of 18
4
jfnsnwrsgfonc72i
8 Mar 21
Kymera Therapeutics / Bruce N. Jacobs ownership change
8:01pm
4
2phzrv
5 Mar 21
Kymera Therapeutics / Bruce N. Jacobs ownership change
5:26pm
4
62rtotupn9ja
3 Mar 21
Kymera Therapeutics / Jared Gollob ownership change
4:57pm
4
vcsfn
3 Mar 21
Kymera Therapeutics / Nello Mainolfi ownership change
4:54pm
4
qomh5i
3 Mar 21
Kymera Therapeutics / Richard Chesworth ownership change
4:52pm
4
urmj7wayv4yzm
3 Mar 21
Kymera Therapeutics / Bruce N. Jacobs ownership change
4:27pm
8-K
gevu07e4
2 Mar 21
KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development
7:15am
4
xyccp
24 Feb 21
Kymera Therapeutics / Jared Gollob ownership change
6:44pm
4
kxm8z7d 767i
22 Feb 21
Change in insider ownership
4:58pm
4
0m54n4l2j d2v409zdz
19 Feb 21
Kymera Therapeutics / Jared Gollob ownership change
7:27pm
SC 13G
3kpqy 27ya2gtp
16 Feb 21
Kymera Therapeutics / Atlas Venture Fund X ownership change
5:27pm
SC 13G
60uvgcof0o fpz8bsqx
16 Feb 21
Kymera Therapeutics / Redmile ownership change
4:10pm
SEC STAFF
rk09jiv
10 Feb 21
SEC staff action: Order
12:00am
SC 13G
knh253djg nj
8 Feb 21
Kymera Therapeutics / FMR ownership change
10:27am
8-K
v67a2uymmpdl0qhn8rrz
12 Jan 21
Kymera Therapeutics Announces Key 2021 Goals and Milestones to Support its
7:17am
10-Q
d4fbo 0d7c
5 Nov 20
Quarterly report
7:31am
8-K
qzi2kuzi79
5 Nov 20
Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update
7:16am
4
t85bcrhkco
9 Sep 20
Kymera Therapeutics / Pamela Esposito ownership change
4:51pm
3
g76ux7dau9nvb44
9 Sep 20
Kymera Therapeutics / Pamela Esposito ownership change
4:46pm
8-K
c3aedwv6 a3ii2sn2bp
9 Sep 20
Departure of Directors or Certain Officers
4:30pm